Objective: To determine whether retinal vein occlusion (RVO) is related to systemic hypertension, diabetes mellitus, and hyperlipidemia.
R ETINAL VEIN OCCLUSION
(RVO) is the second most common form of retinal vascular disease causing vision loss. 1 Branch RVO (BRVO) may result from compression of a branch retinal vein by an adjacent retinal artery, typically at a common crossing point. Central RVO (CRVO) typically arises when the central retinal vein is occluded posterior to or within the lamina cribrosa. 1, 2 Retinal hemorrhage and edema may complicate either form of RVO, resulting in partial or complete loss of vision. Neovascularization of the iris, anterior chamber angle, and retina in CRVO and BRVO may be a further complication. 1, 2 Although thrombophilia defects are often associated with lower limb deep vein thrombosis and pulmonary embolism, they are frequently absent in persons with RVO. 3 In a recent meta-analysis by Janssen et al, only hyperhomocysteinemia and the presence of anticardiolipin antibodies were more prevalent in persons with RVO. 3 In their conclusions, the authors questioned whether conventional systemic risk factors for atherosclerosis play a dominant role in the pathogenesis of RVO. We undertook a meta-analysis to compare 3 common risk factors for atherosclerosis-hypertension, diabetes mellitus, and hyperlipidemia-in persons with and without RVO.
METHODS

LITERATURE SEARCH
Two investigators (P.R.A.O. and J.G.R.) independently searched the PubMed and EMBASE databases for articles published from January 1985 to July 2007. The following search expression was used: "(retinal vein) AND (thrombosis OR occlusion OR obstruction) AND (hypertension OR diabetes mellitus OR dyslipidemia OR hyperlipidemia OR lipids OR cholesterol)." All searches were limited to English language and human subject studies.
The abstract of each article was read and determined to be eligible according to the following criteria: (1) the study included at least 10 cases with any form of RVO; (2) a control group without RVO was included; and (3) the number of cases and controls with hypertension, diabetes mellitus, and/or hyperlipidemia was also reported in the study. Full-text articles deemed eligible were reviewed to ensure that they met the inclusion criteria.
DATA ABSTRACTION
Study design and patient characteristics, methods used to define atherosclerosis risk factors, and the prevalence of risk factors in cases and controls were put into standardized tables. Hemiretinal vein occlusion was considered to be a variant of CRVO, in keeping with the studies included herein and the recommendations of others. 2, 4 If there was any uncertainty about a study's data, the corresponding author was contacted by e-mail.
STATISTICAL ANALYSIS
Among persons with and without RVO, a DerSimonian-Laird random-effects model was used to derive a pooled prevalence and 95% confidence interval (CI) for each atherosclerosis risk factor. 5 This was separately performed for any type of RVO, CRVO, and BRVO. This random-effects method weights the relative contribution of each study to a pooled event rate based on the variance both within and among studies. 5 Statistical heterogeneity for the pooled event rate was determined using the Breslow-Day method, with P Ͻ .05 representing significant heterogeneity. 6 For studies of any type of RVO, CRVO, and BRVO, an odds ratio (OR) and 95% CI were also calculated for each atherosclerosis risk factor, comparing persons with vs those without RVO. Derivation of a pooled OR and 95% CI, along with testing for statistical heterogeneity, were performed with the same meta-analytical methods, 5, 6 using Meta-Analyst statistical software. 7 For any type of RVO, as well as CRVO and BRVO, the population-attributable risk percentage (PAR%; the percentage attributed to each atherosclerosis risk factor [ie, hypertension, diabetes mellitus, and hyperlipidemia]) was calculated for each atherosclerosis risk factor using the following equation: A 95% CI for the PAR% was also derived with this above equation, using the upper and lower 95% CI for the pooled OR for each risk factor, as well as the upper and lower 95% CI for the pooled rate among unaffected controls.
RESULTS
STUDY AND PARTICIPANT CHARACTERISTICS
A total of 295 citations were initially found in PubMed and 215 in EMBASE. Of these, 20 articles comprising 21 studies met the inclusion criteria ( Table 1) . [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Nine of 21 studies were from the United States, 3 from Italy, 3 from Turkey, and 1 each from Armenia, Australia, Austria, Iran, Israel, and Japan. All but 4 were case-control studies: 2 were cross-sectional studies 10, 23 and 2 were cohort studies. 27 Of 2916 people with RVO, 1398 (47.9%) had CRVO and 1518 (52.1%) had BRVO (Table 1) . Controls typically were recruited from ophthalmology practices at the same center or from the same region as the RVO cases. Most cases and controls were aged 60 to 65 years. Two studies used the same control group. 13, 14 
ATHEROSCLEROSIS RISK FACTORS AND RVO
All studies assessed cases with RVO for the presence of hypertension, 20 assessed for diabetes mellitus, and 9 for hyperlipidemia ( Table 2 ). The methods used to define the presence of hypertension varied across studies. In most studies, hypertension was defined as a documented elevated blood pressure measurement, although a history of hypertension was also used. In addition, the definitions of diabetes mellitus and hyperlipidemia also varied among studies (Table 2) .
SYSTEMIC HYPERTENSION
Among 2916 persons with any form of RVO, the pooled prevalence of systemic hypertension was 63.6% (95% CI, 58.9%-68.1%) compared with 36.2% (95% CI, 30.7%-42.2%) among 28 646 unaffected controls, which was equivalent to a pooled OR of 3.5 (95% CI, 2.5-5.1) ( Table 3 and Figure, A) . Although most studies described a positive association between hypertension and RVO ( Figure, A) , a significant degree of heterogeneity was present for the pooled estimates. Of 21 studies, 1 found a higher rate of hypertension among controls, but the difference was not significant, and the method used to define hypertension was not described. 12 The PAR% for hypertension among persons with any form of RVO was 47.9% (95% CI, 31.2%-63.1%) ( Table 3) . A significant association was seen between hypertension and both CRVO (pooled OR, 3.8; 95% CI, 1.9-7.4) ( Table 4) and BRVO (pooled OR, 3.0; 95% CI, 2.0-4.4) ( Table 5) .
DIABETES MELLITUS
Diabetes mellitus was slightly more prevalent among 2877 cases with any form of RVO (14.6%; 95% CI, 12.3%-17.3%) than the 13 225 unaffected controls (11.1%, 95% CI, 9.2%-13.4%) ( Table 3 and Figure, B ). Although the pooled OR was significant (1.5; 95% CI, 1.1-2.0), the risk of RVO was not consistently higher in all studies, with opposing results in 4 studies. 15, 22, 24, 25 The PAR% for diabetes mellitus among persons with any form of RVO was 4.9% (95% CI, 0.8%-11.5%) ( Table 3) . Although CRVO (pooled OR, 2.0; 95% CI, 1.2-3.4) ( Table 4 ) was significantly associated with the presence of diabetes mellitus, BRVO (pooled OR, 1.1; 95% CI, 0.8-1.5) was not (Table 5) .
HYPERLIPIDEMIA
Hyperlipidemia was not defined in a consistent manner across studies, and in some studies, no definition was provided (Table 2) . 16, 18, 20 For any form of RVO, hyperlipidemia was more than twice as common among the 1393 cases (35.1%; 95% CI, 22.0%-51.0%) than the 2642 controls (16.7%; 95% CI, 9.1%-28.6%), equivalent to a pooled OR of 2.5 (95% CI, 1.7-3.7) ( Table 3 and Figure, C ). These pooled estimates were statistically heterogeneous, however. Similar significant risk estimates were seen for persons with CRVO (Table 4 ) and BRVO ( Table 5 ). The PAR% for hyperlipidemia among persons with any form of RVO was 20.1% (95% CI, 5.9%-43.8%) ( 
COMMENT
In this meta-analysis of 21 observational studies including 2915 persons with RVO, we observed a more than 3.5-times higher risk of RVO in cases with systemic hypertension. About a 2.5-times higher risk of RVO was associated with hyperlipidemia, but there was only a modest correlation between RVO and the presence of diabetes mellitus.
LIMITATIONS
The definitions of hypertension, diabetes mellitus, and hyperlipidemia varied both within and among studies ( Table 2) . This was partly due to the changing diagnostic criteria for each condition during the 2 decades of study and the lack of formal measurements from close to the time of RVO onset. In fact, the time of onset of RVO symptoms was rarely considered in relation to each atherosclerosis risk factor. The time between RVO onset and case enrollment varied from weeks 16, 24 to 2 years. 17 Some studies did not define a given atherosclerosis risk factor, 12, 16, 18, 20, 24 and in most studies, the severity of hypertension or hyperlipidemia was not reported. Although many studies matched controls to cases on age and sex, they did not control for other relevant factors, such as body mass index, renal function, smoking, or intraocular pressure. The latter is important because ocular hypertension, which is also associated with systemic hypertension, is a probable risk factor for RVO. 11, 14, 19 Previously, some studies have distinguished between ischemic and nonischemic RVO, 14 which was not a consideration in most studies included in this meta-analysis. Although combining hemiretinal vein occlusion with CRVO might be questioned, they share similar anatomical features and pathogenesis.
2,4 Finally, we did not attempt to include unpublished or non-English language studies. Taken together, these points may limit the external validity of our risk estimates, especially in the modern era of bettercontrolled hypertension and dyslipidemia.
SOURCES OF HETEROGENEITY
Statistical heterogeneity was present for most of the pooled risk estimates. In addition to study differences, including the definition of each risk factor and the interval between RVO onset and its assessment, the method of selecting controls varied largely among studies. Some studies were designed to assess for risk factors other than hypertension, diabetes mellitus, and hyperlipidemia as their main exposure of interest. 12, [15] [16] [17] [18] [20] [21] [22] [24] [25] [26] This likely manifested as a high degree of variability in the rate of hypertension among controls vs participants with any form of (Table 3) , resulting in a high degree of variation in the associated pooled OR (Figure, A) . In some studies, the OR may have been further inflated by the biased selection of exceptionally healthy controls, whose reported rates of hypertension and diabetes mellitus were less than 10% and 1%, respectively. 17, 19, 26 Although a significant degree of statistical heterogeneity was found in this meta-analysis, there was a consistently positive association across studies between RVO and both hypertension and hyperlipidemia ( Figure, A and C) , suggesting that these findings are robust.
IMPLICATIONS
This meta-analysis explored whether RVO may be caused by traditional risk factors for atherosclerosis. 3 The pronounced PAR% for hypertension (nearly 50%), hyperlipidemia (20%), and diabetes mellitus (5%) in persons with RVO, if causal, would mean that treatment of these diseases might be important in the primary and secondary prevention of RVO. This would be in addition to the prevention of heart disease and stroke, for which there is high-quality evidence.
28,29 Accordingly, we recommend that an assessment of blood pressure and both fasting lipid and glucose levels be routinely performed in adults with any form of RVO. At the same time, evidence is lacking about whether lowering blood pressure, serum lipid levels, and/or blood glucose levels can improve visual acuity or the complications of RVO. Hence, a sensible approach is to gradually normalize these measures in accordance with current guidelines, 28, 29 with the main goal being the prevention of cardiovascular and renal disease.
FUTURE RESEARCH
Further observational studies should use standardized measurements and definitions of hypertension, diabetes mellitus, and dyslipidemia, each assessed near the time of RVO diagnosis. As was mentioned elsewhere, 2 data are needed to determine whether excessive lowering of blood pressure in persons with RVO may have negative effects during the acute phase of the disease, and whether it can reduce the long-term risk of neovascular glaucoma or RVO recurrence.
There is a paucity of level 1 evidence regarding the treatment of CRVO and BRVO, including the use of systemic therapy. 30, 31 Moreover, some conventional antithrombotic medications do not appear to be protective against RVO and may be harmful. For example, in a recently published case-control study, Koizumi et al found that use of aspirin (OR, 2.66; 95% CI, 1.52-4.64) and warfarin (OR, 3.34; 95% CI, 1.44-7.80) was significantly associated with a higher risk of CRVO. 32 In an effort to better define the role of lipid reduction in persons with RVO, we have embarked on the Atorvastatin Toronto Retinal Vein Occlusion (ATORVO) study (Trial Registration clinicaltrials.gov identifier: NRA2580025). The ATORVO study is an investigator-initiated randomized, double-masked clinical trial comparing 80 mg of atorvastatin calcium once a day to placebo in 180 persons with RVO. Changes in Yildirimetal, 21 2004 Weger et al, 22 2005 Wong et al, 23 2005 Gumus et al, 24 2006 Pinna et al, 25 2007 Leoncini et al, 26 2007 Cugati et al, 27 Appiah and Greenidge, 7 1987 Elman et al, 10 1990 Rath et al, 11 1992 Sekimoto et al, 12 1992 Sperduto et al, 13 1993 Eye Disease Case-Control Study Group, 14 1996 Simons and Brucker, 15 1997 Salomon et al, 16 1998 Marcucci et al, 17 2001 Kadayifçilar et al, 18 2001 Shahsuvaryan and Melkonyan, 19 2003 Yaghoubi et al, 20 2004 Yildirim et al, 21 2004 Weger et al, 22 2005 Gumus et al, 24 2006 Pinna et al, 25 2007 Leoncini et al, 26 2007 Cugati et al, 27 Sperduto et al, 13 1993 Salomon et al, 16 1998 Marcucci et al, 17 2001 Kadayifçilar et al, 18 2001 Yaghoubi et al, 20 2004 Weger et al, 22 2005 Pinna et al, 25 2007 Leoncini et al, 26 visual acuity and the presence of secondary complications of RVO will be evaluated 24 weeks after randomization (study protocol available by e-mailing the corresponding author).
CONCLUSIONS
Those who treat patients with systemic hypertension, diabetes mellitus, and hyperlipidemia should consider that each poses a risk not only to cardiovascular health but also to ocular health. 33 The current findings suggest that a major proportion of RVO cases are caused by highly prevalent atherosclerosis risk factors that can be measured in a routine clinical setting. 
